Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + Nab-Paclitaxel + S-1 vs FOLFOX in 2L Advanced BTC
NCT06662877Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2024
- Primary completion
- Sep 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of anlotinib in biliary tract cancer (BTC), sponsored by Sun Yat-sen University. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06662877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06662877.